Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

NCT05277051 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05277051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05277051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 22, 2022
Completion date
August 31, 2027
Enrollment
152 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms